Voor de beste ervaring schakelt u JavaScript in en gebruikt u een moderne browser!
Je gebruikt een niet-ondersteunde browser. Deze site kan er anders uitzien dan je verwacht.
What policies and practices have been successful in regulating the prices and procurement of vaccines, medicines, and other health products? LCHL’s dr. Katrina Perehudoff contributed evidence from her research to answer this question, which was the subject of an open consultation by the Office of the High Commissioner for Human Rights (OHCHR).

The OHCHR was seeking contributions to shape the forthcoming Human Rights Council Resolution 50/13 on Good practices to ensuring access to medicines, vaccines and other health products.

Katrina collaborated with Medicines Law & Policy – an implementing partner in her Veni project – to present evidence from their research on compulsory licensing (see article in BMJ Global Health). The key message to OHCHR was that compulsory licensing (a flexibility enshrined in the TRIPS Agreement) and data/market exclusivity waivers as policies and practices to regulate the prices and aid in the procurement of vaccines, medicines and other health products that are patent protected.

Katrina’s contribution was part of her ongoing research exploring the EU’s role in global access to medicines, which is supported in part by a Veni talent grant from the Netherlands Organisation of Scientific Research and the Amsterdam University Funds.